{"prompt": "['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 52 of 74', 'detailing the frequency and scope of the monitoring for the trial. Throughout the course', 'of the trial, the risk assessment will be reviewed and the monitoring frequency adjusted', 'as necessary.', 'Remote monitoring will be conducted for all participating sites. The scope and frequency', 'of the monitoring will be determined by the risk assessment and detailed in the', 'Monitoring Plan for the trial.', '20 Protocol Compliance and Breaches of GCP', 'Prospective, planned deviations or waivers to the protocol are not allowed under the UK', 'regulations on Clinical Trials and must not be used.', 'Protocol deviations, non-compliances, or breaches are departures from the approved', 'protocol. They can happen at any time, but are not planned. They must be adequately', 'documented on the relevant forms and reported to the Chief Investigator and Sponsor', 'immediately.', 'Deviations from the protocol which are found to occur constantly again and again will', 'not be accepted and will require immediate action and could potentially be classified as', 'a serious breach.', 'Any potential/suspected serious breaches of GCP must be reported immediately to the', 'Sponsor without any delay.', '21 Publications policy', 'Ownership of the data arising from this trial resides with the TMG. On completion of the', 'trial the data will be analysed and tabulated and a Final Trial Report prepared.', 'The main trial results will be presented at national and international conferences and', 'published in a peer-reviewed journal, on behalf of all collaborators. All presentations', 'and publications relating to the trial must be authorised by the TMG.', 'The manuscript will be prepared by a writing group appointed from amongst the TMG', 'and high-accruing investigators. The CCTU-CT, NIHR, CRUK and all participating sites', 'and Investigators will be acknowledged in publications and presentations. Senior', 'authorship shall be shared between members of the TMG according to their leadership', 'role in the trial. Priority will be given to the lead sites (Cambridge and Oxford) co-', 'ordinating the trial, then to participating sites, ordered by recruitment.', 'In addition patients who have consented to receive updates on trial progress and', 'results of the trial, will be provided with trial updates and summary of the results in lay', 'terms.', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 53 of 74', '22 References', '1.', 'Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF', 'V600E mutation. N Eng J Med 364, 2507-2516 (2011).', '2.', 'Hauschild, A. et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre,', 'open-label, phase 3 randomised controlled trial. Lancet 380, 358-365 (2012).', '3.', 'Alcal\u00e1, Alexander Marzuka, Flaherty, K. T. BRAF inhibitors for the treatment of', 'metastatic melanoma: clinical trials and mechanisms of resistance. Clin. Cancer Res.', '18, 33-9 (2012).', '4.', 'Robert, C. et al. Improved Overall Survival in Melanoma with Combined Dabrafenib', 'and Trametinib. N. Engl. J. Med. 372, 141116004513004 (2014).', '5.', 'Long, G. V. et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600', 'BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled', 'trial. Lancet 386, 444-451 (2015).', '6.', 'Ascierto, P. A. et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-', 'mutant melanoma (coBRIM): updated efficacy results from a randomised, double-', 'blind, phase 3 trial. Lancet Oncol. 17, 1248-1260 (2016).', '7.', 'Welsh, S. J. & Corrie, P. G. Management of BRAF and MEK inhibitor toxicities in', 'patients with metastatic melanoma. Ther. Adv. Med. Oncol. 7, 122-36 (2015).', '8.', 'Larkin, J. et al. Vemurafenib in patients with BRAF(V600) mutated metastatic', 'melanoma: an open-label, multicentre, safety study. Lancet Oncol. Oncol. 436-444,', '(2014).', '9.', 'Dooley, A. J., Gupta, A., Bhattacharyya, M. & Middleton, M. R. Intermittent dosing', 'with vemurafenib in BRAF V600E-mutant melanoma: review of a case series. Ther.', 'Adv. Med. Oncol. 6, 262-6 (2014).', '10.', 'Das Thakur, M. et al. Modelling vemurafenib resistance in melanoma reveals a', 'strategy to forestall drug resistance. Nature 494, 251-255 (2013).', '11.', 'Seghers, A., Wilgenhof, S., Lebbe, C. & Neyns, B. Successful rechallenge in two', 'patients with BRAF-V600-mutant melanoma who experienced previous progression', 'during treatment with a selective BRAF inhibitor. Melanoma Res. December 2, 466-', '472 (2012).', '12.', 'Poulikakos, P. I. et al. RAF inhibitor resistance is mediated by dimerization of', 'aberrantly spliced BRAF(V600E). Nature 480, 387-90 (2011).', '13.', 'Belum, V. R., Fischer, A., Choi, J. N. & Lacouture, M. E. Dermatological adverse', 'events from BRAF inhibitors: A growing problem. Curr. Oncol. Rep. 15, 249-259', '(2013).', '14.', 'Gencler, B. & Gonul, M. Cutaneous side effects of BRAF inhibitors in advanced', 'melanoma: Review of the literature. Dermatology Research and Practice 2016,', '(2016).', '15.', 'Lacroix, J. & Wang, B. Prospective Case Series of Cutaneous Adverse Effects', 'Associated With Dabrafenib and Trametinib. J. Cutan. Med. Surg. 21, (2016).', '16.', 'Carlos, G. et al. Cutaneous toxic effects of BRAF inhibitors alone and in combination', 'with MEK inhibitors for metastatic melanoma. JAMA dermatology 151, 1103-9', '(2015).', '17.', 'Sanlorenzo, M. et al. Comparative profile of cutaneous adverse events: BRAF/MEK', 'inhibitor combination therapy versus BRAF monotherapy in melanoma. J. Am. Acad.', 'Dermatol. 71, 1102-1109.e1 (2014).', '18. de Golian, E., Kwong, B. Y., Swetter, S. M. & Pugliese, S. B. Cutaneous Complications', 'of Targeted Melanoma Therapy. Current Treatment Options in Oncology 17, (2016).', '19.', 'Chan, A. et al. A systematic review of patient-reported outcome instruments of', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']\n\n###\n\n", "completion": "END"}